This chapter examines the competitive dynamics of the GLP-1 diet drug market, spotlighting Eli Lilly and Novo Nordisk's contrasting performances. It highlights Eli Lilly's recent success and strategic advantages, while addressing Novo's challenges amidst rising pressure. The discussion also touches on the societal impacts of these drugs, particularly in Bowling Green, Kentucky, and personal stories of individuals navigating the complexities of weight-loss treatments.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode